Lava Ventures

LAVA Therapeutics is a clinical-stage immuno-oncology company focused on developing a proprietary portfolio of bispecific gamma delta T cell engagers for the treatment of cancer. The company's Gammabody platform generates bispecific antibodies that are designed to redirect gamma delta T cells to selectively target and kill tumor cells while sparing healthy tissue. Their lead programs include LAVA-1207, which targets PSMA-positive prostate cancer, and LAVA-1223, which targets EGFR-expressing solid tumors. By leveraging the unique properties of Vγ9Vδ2 T cells, LAVA aims to provide potent and durable anti-tumor responses with a favorable safety profile compared to traditional T cell engagers.